Glaucoma Market Share, Size, Trends, Industry Analysis Report, By Drug Class; By Distribution Channel (Hospital pharmacy, Retail pharmacy, and Online pharmacy); By Disease Type; By Region; Segment Forecast, 2023 - 2032
Description
Glaucoma Market Share, Size, Trends, Industry Analysis Report, By Drug Class; By Distribution Channel (Hospital pharmacy, Retail pharmacy, and Online pharmacy); By Disease Type; By Region; Segment Forecast, 2023 - 2032
The global glaucoma market size is expected to reach USD 9,154.4 million by 2032, according to a new study by Polaris Market Research. The report “Glaucoma Market Share, Size, Trends, Industry Analysis Report, By Drug Class; By Distribution Channel (Hospital pharmacy, Retail pharmacy, and Online pharmacy); By Disease Type; By Region; Segment Forecast, 2023 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Glaucoma, a prevalent ocular condition, is expected to affect many individuals worldwide. The World Glaucoma Association predicts the disease will impact 79.6 million people in 2020 and rise to 111.8 million by 2040. In the United States alone, glaucoma affects 3 million people, with 2.7 million of them being over 40. The increasing incidence rates and advancements in therapeutic strategies are driving the expansion of the glaucoma market.
Technological improvements in the ophthalmology sector play a significant role in the positive outlook for the glaucoma market. The demand for cutting-edge surgical techniques, such as micro-invasive glaucoma surgery (MIGS) and selective laser trabeculoplasty (SLT), is driving industry growth. Moreover, advancements in medical imaging, optical coherence tomography (OCT), and progression analysis software are increasing the popularity of optometrists. Incorporating laser therapies as first-line treatments and developing new medications for glaucoma also contribute to the market's expansion.
The COVID-19 pandemic had adverse effects on the sales of glaucoma treatments. Preventive lockdown measures and diverted healthcare resources limited access to care for glaucoma patients. Many ophthalmology clinics were repurposed as COVID-19 wards, which hindered patient follow-ups. Furthermore, the fear of contracting the virus deterred older individuals from visiting clinical settings, decreasing market demand. However, telemedicine platforms emerged as a viable solution during the pandemic, enabling patients to access prompt care and contributing to the overall expansion of the industry.
Glaucoma Market Report Highlights
The prostaglandin analogs segment held the largest share of the glaucoma market. Their widespread use, effectiveness with once-daily dosing, and benefits in combination therapy contribute to the segment's projected growth and market dominance.
The open-angle disease type is the dominant segment in the glaucoma market due to its high prevalence and available therapeutic medications specifically designed for its treatment.
North America is dominant in the glaucoma market due to its well-developed hospital infrastructure, effective treatment framework, and increasing FDA approvals and drug launches.
The global key market players include Allergan PLC, Aristo Pharmaceuticals Pvt. Ltd., Aerie Pharmaceuticals Company, Akorn operating company LLC, Bausch & Lomb Incorporated, Cipla Incorporation, Fera Pharmaceuticals, LLC, Inotek Pharmaceuticals, Merck KGaA, Novartis AG, Pfizer Incorporation, Santen Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., and Valeant Pharmaceuticals International, Inc.
Polaris Market Research has segmented the Glaucoma market report based on drug class, distribution channel, disease type, and region:
Glaucoma, Drug Class Outlook (Revenue - USD Million, 2019 - 2032)
Prostaglandin Analogs
Beta-blockers
Adrenergic Agonists
Carbonic Anhydrase Inhibitors
Others
Glaucoma, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)
Hospital pharmacy
Retail pharmacy
Online Pharmacy
Glaucoma, Disease Type Outlook (Revenue - USD Million, 2019 - 2032)
Open-angle
Angle-closure
Others
Glaucoma, Regional Outlook (Revenue - USD Million, 2019 - 2032)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Latin America
Argentina
Brazil
Mexico
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Table of Contents
114 Pages
- 1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
- 2. Executive Summary
- 2.1. Market Highlights
- 3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
- 4. Global Glaucoma Market Insights
- 4.1. Glaucoma Market – Disease Type Snapshot
- 4.2. Glaucoma Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increasing Collaboration And Partnerships Among The Industry’s Key Players
- 4.2.1.2. Novel Product Launch
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Lack Of Awareness And Underdiagnoses Of The Disease
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Glaucoma Market Disease Type Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
- 5. Global Glaucoma Market, by Drug Class
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Glaucoma Market, by Drug Class, 2019-2032 (USD Million)
- 5.3. Prostaglandin Analogs
- 5.3.1. Global Glaucoma Market, by Prostaglandin Analogs, by Region, 2019-2032 (USD Million)
- 5.4. Beta-blockers
- 5.4.1. Global Glaucoma Market, by Beta-blockers, by Region, 2019-2032 (USD Million)
- 5.5. Adrenergic Agonists
- 5.5.1. Global Glaucoma Market, by Adrenergic Agonists, by Region, 2019-2032 (USD Million)
- 5.6. Carbonic Anhydrase Inhibitors
- 5.6.1. Global Glaucoma Market, by Carbonic Anhydrase Inhibitors, by Region, 2019-2032 (USD Million)
- 5.7. Others
- 5.7.1. Global Glaucoma Market, by Others, by Region, 2019-2032 (USD Million)
- 6. Global Glaucoma Market, by Distribution Channel
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Glaucoma Market, by Distribution Channel, 2019-2032 (USD Million)
- 6.3. Hospital pharmacy
- 6.3.1. Global Glaucoma Market, by Hospital pharmacy, by Region, 2019-2032 (USD Million)
- 6.4. Retail pharmacy
- 6.4.1. Global Glaucoma Market, by Retail pharmacy, by Region, 2019-2032 (USD Million)
- 6.5. Online Pharmacy
- 6.5.1. Global Glaucoma Market, by Online Pharmacy, by Region, 2019-2032 (USD Million)
- 7. Global Glaucoma Market, by Disease Type
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Glaucoma Market, by Disease Type, 2019-2032 (USD Million)
- 7.3. Open-angle
- 7.3.1. Global Glaucoma Market, by Open-angle, By Region, 2019-2032 (USD Million)
- 7.4. Angle-closure
- 7.4.1. Global Glaucoma Market, by Angle-closure, By Region, 2019-2032 (USD Million)
- 7.5. Others
- 7.5.1. Global Glaucoma Market, by Others, By Region, 2019-2032 (USD Million)
- 8. Global Glaucoma Market, by Geography
- 8.1. Key findings
- 8.2. Introduction
- 8.2.1. Glaucoma Market Assessment, By Geography, 2019-2032 (USD Million)
- 8.3. Glaucoma Market – North America
- 8.3.1. North America: Glaucoma Market, by Drug Class, 2019-2032 (USD Million)
- 8.3.2. North America: Glaucoma Market, by Disease Type, 2019-2032 (USD Million)
- 8.3.3. North America: Glaucoma Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.3.4. Glaucoma Market – U.S.
- 8.3.4.1. U.S.: Glaucoma Market, by Drug Class, 2019-2032 (USD Million)
- 8.3.4.2. U.S.: Glaucoma Market, by Disease Type, 2019-2032 (USD Million)
- 8.3.4.3. U.S.: Glaucoma Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.3.5. Glaucoma Market – Canada
- 8.3.5.1. Canada: Glaucoma Market, by Drug Class, 2019-2032 (USD Million)
- 8.3.5.2. Canada.: Glaucoma Market, by Disease Type, 2019-2032 (USD Million)
- 8.3.5.3. Canada: Glaucoma Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4. Glaucoma Market – Europe
- 8.4.1. Europe: Glaucoma Market, by Drug Class, 2019-2032 (USD Million)
- 8.4.2. Europe.: Glaucoma Market, by Disease Type, 2019-2032 (USD Million)
- 8.4.3. Europe: Glaucoma Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.4. Glaucoma Market – UK
- 8.4.4.1. UK: Glaucoma Market, by Drug Class, 2019-2032 (USD Million)
- 8.4.4.2. UK.: Glaucoma Market, by Disease Type, 2019-2032 (USD Million)
- 8.4.4.3. UK: Glaucoma Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.5. Glaucoma Market – France
- 8.4.5.1. France: Glaucoma Market, by Drug Class, 2019-2032 (USD Million)
- 8.4.5.2. France.: Glaucoma Market, by Disease Type, 2019-2032 (USD Million)
- 8.4.5.3. France: Glaucoma Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.6. Glaucoma Market – Germany
- 8.4.6.1. Germany: Glaucoma Market, by Drug Class, 2019-2032 (USD Million)
- 8.4.6.2. Germany.: Glaucoma Market, by Disease Type, 2019-2032 (USD Million)
- 8.4.6.3. Germany: Glaucoma Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.7. Glaucoma Market – Italy
- 8.4.7.1. Italy: Glaucoma Market, by Drug Class, 2019-2032 (USD Million)
- 8.4.7.2. Italy.: Glaucoma Market, by Disease Type, 2019-2032 (USD Million)
- 8.4.7.3. Italy: Glaucoma Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.8. Glaucoma Market – Spain
- 8.4.8.1. Spain: Glaucoma Market, by Drug Class, 2019-2032 (USD Million)
- 8.4.8.2. Spain.: Glaucoma Market, by Disease Type, 2019-2032 (USD Million)
- 8.4.8.3. Spain: Glaucoma Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.9. Glaucoma Market – Netherlands
- 8.4.9.1. Netherlands: Glaucoma Market, by Drug Class, 2019-2032 (USD Million)
- 8.4.9.2. Netherlands.: Glaucoma Market, by Disease Type, 2019-2032 (USD Million)
- 8.4.9.3. Netherlands: Glaucoma Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.10. Glaucoma Market – Russia
- 8.4.10.1. Russia: Glaucoma Market, by Drug Class, 2019-2032 (USD Million)
- 8.4.10.2. Russia.: Glaucoma Market, by Disease Type, 2019-2032 (USD Million)
- 8.4.10.3. Russia: Glaucoma Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5. Glaucoma Market – Asia Pacific
- 8.5.1. Asia Pacific: Glaucoma Market, by Drug Class, 2019-2032 (USD Million)
- 8.5.2. Asia Pacific.: Glaucoma Market, by Disease Type, 2019-2032 (USD Million)
- 8.5.3. Asia Pacific: Glaucoma Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.4. Glaucoma Market – China
- 8.5.4.1. China: Glaucoma Market, by Drug Class, 2019-2032 (USD Million)
- 8.5.4.2. China.: Glaucoma Market, by Disease Type, 2019-2032 (USD Million)
- 8.5.4.3. China: Glaucoma Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.5. Glaucoma Market – India
- 8.5.5.1. India: Glaucoma Market, by Drug Class, 2019-2032 (USD Million)
- 8.5.5.2. India.: Glaucoma Market, by Disease Type, 2019-2032 (USD Million)
- 8.5.5.3. India: Glaucoma Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.6. Glaucoma Market – Malaysia
- 8.5.6.1. Malaysia: Glaucoma Market, by Drug Class, 2019-2032 (USD Million)
- 8.5.6.2. Malaysia.: Glaucoma Market, by Disease Type, 2019-2032 (USD Million)
- 8.5.6.3. Malaysia: Glaucoma Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.7. Glaucoma Market – Japan
- 8.5.7.1. Japan: Glaucoma Market, by Drug Class, 2019-2032 (USD Million)
- 8.5.7.2. Japan.: Glaucoma Market, by Disease Type, 2019-2032 (USD Million)
- 8.5.7.3. Japan: Glaucoma Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.8. Glaucoma Market – Indonesia
- 8.5.8.1. Indonesia: Glaucoma Market, by Drug Class, 2019-2032 (USD Million)
- 8.5.8.2. Indonesia.: Glaucoma Market, by Disease Type, 2019-2032 (USD Million)
- 8.5.8.3. Indonesia: Glaucoma Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.9. Glaucoma Market – South Korea
- 8.5.9.1. South Korea: Glaucoma Market, by Drug Class, 2019-2032 (USD Million)
- 8.5.9.2. South Korea.: Glaucoma Market, by Disease Type, 2019-2032 (USD Million)
- 8.5.9.3. South Korea: Glaucoma Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.6. Glaucoma Market – Middle East & Africa
- 8.6.1. Middle East & Africa: Glaucoma Market, by Drug Class, 2019-2032 (USD Million)
- 8.6.2. Middle East & Africa.: Glaucoma Market, by Disease Type, 2019-2032 (USD Million)
- 8.6.3. Middle East & Africa: Glaucoma Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.6.4. Glaucoma Market – Saudi Arabia
- 8.6.4.1. Saudi Arabia: Glaucoma Market, by Drug Class, 2019-2032 (USD Million)
- 8.6.4.2. Saudi Arabia.: Glaucoma Market, by Disease Type, 2019-2032 (USD Million)
- 8.6.4.3. Saudi Arabia: Glaucoma Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.6.5. Glaucoma Market – UAE
- 8.6.5.1. UAE: Glaucoma Market, by Drug Class, 2019-2032 (USD Million)
- 8.6.5.2. UAE.: Glaucoma Market, by Disease Type, 2019-2032 (USD Million)
- 8.6.5.3. UAE: Glaucoma Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.6.6. Glaucoma Market – Israel
- 8.6.6.1. Israel: Glaucoma Market, by Drug Class, 2019-2032 (USD Million)
- 8.6.6.2. Israel.: Glaucoma Market, by Disease Type, 2019-2032 (USD Million)
- 8.6.6.3. Israel: Glaucoma Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.6.7. Glaucoma Market – South Africa
- 8.6.7.1. South Africa: Glaucoma Market, by Drug Class, 2019-2032 (USD Million)
- 8.6.7.2. South Africa.: Glaucoma Market, by Disease Type, 2019-2032 (USD Million)
- 8.6.7.3. South Africa: Glaucoma Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.7. Glaucoma Market – Latin America
- 8.7.1. Latin America: Glaucoma Market, by Drug Class, 2019-2032 (USD Million)
- 8.7.2. Latin America.: Glaucoma Market, by Disease Type, 2019-2032 (USD Million)
- 8.7.3. Latin America: Glaucoma Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.7.4. Glaucoma Market – Mexico
- 8.7.4.1. Mexico: Glaucoma Market, by Drug Class, 2019-2032 (USD Million)
- 8.7.4.2. Mexico.: Glaucoma Market, by Disease Type, 2019-2032 (USD Million)
- 8.7.4.3. Mexico: Glaucoma Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.7.5. Glaucoma Market – Brazil
- 8.7.5.1. Brazil: Glaucoma Market, by Drug Class, 2019-2032 (USD Million)
- 8.7.5.2. Brazil.: Glaucoma Market, by Disease Type, 2019-2032 (USD Million)
- 8.7.5.3. Brazil: Glaucoma Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.7.6. Glaucoma Market – Argentina
- 8.7.6.1. Argentina: Glaucoma Market, by Drug Class, 2019-2032 (USD Million)
- 8.7.6.2. Argentina.: Glaucoma Market, by Disease Type, 2019-2032 (USD Million)
- 8.7.6.3. Argentina: Glaucoma Market, by Distribution Channel, 2019-2032 (USD Million)
- 9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
- 10. Company Profiles
- 10.1. Allergan PLC
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Aristo Pharmaceuticals Pvt. Ltd
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Aerie Pharmaceuticals Company
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Akorn operating company LLC
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Bausch & Lomb Incorporated
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Cipla Incorporation
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Fera Pharmaceuticals, LLC
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Inotek Pharmaceuticals
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Merck KGaA
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Novartis AG
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
- 10.11. Pfizer Incorporation
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
- 10.12. Santen Pharmaceutical Co., Ltd
- 10.12.1. Company Overview
- 10.12.2. Financial Performance
- 10.12.3. Product Benchmarking
- 10.12.4. Recent Development
- 10.13. Teva Pharmaceutical Industries Ltd
- 10.13.1. Company Overview
- 10.13.2. Financial Performance
- 10.13.3. Product Benchmarking
- 10.13.4. Recent Development
- 10.14. Valeant Pharmaceuticals International, Inc
- 10.14.1. Company Overview
- 10.14.2. Financial Performance
- 10.14.3. Product Benchmarking
- 10.14.4. Recent Development
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
